Tim Barder Joins Clarion as Senior Principal
Clarion is pleased to announce that Tim Barder has joined the firm as a Senior Principal. Tim brings over 14 years of experience in the life science industry, first as a bench scientist, where he led numerous drug discovery and nanoparticle drug delivery programs to most recently as a consultant, where he has been advising global pharmaceutical, early-stage biotech, CDMO, and investment firm clients. Tim’s expertise is in innovation strategy management, where he generates actionable recommendations on growth opportunities for clients, enabling them to apply their cutting-edge science towards areas of greatest patient need and in a way that responsibly drives toward commercial sustainability.
“We are thrilled that Tim has joined the Clarion Leadership Team,“ says Tom Murtagh, Clarion CEO and Founder. “Clarion has always been deeply committed to helping its clients successfully navigate the intersection of disruptive technology, clinical practice, and the commercial landscape. The depth of Tim’s R&D experience will extend the Clarion team’s capability – allowing us to richly explore the opportunities and challenges associated with some of the newest and most promising technologies that are seeking to disrupt care. Tim’s intimate understanding of the practical challenges in advancing technology to the clinic will enhance our ability to develop clear scenarios for program candidates and help Senior Leadership teams better gauge risk around technology programs and platforms. We look forward to Tim’s contribution to our clients and the firm through his role on the Clarion Leadership Team.”
Prior to joining Clarion, Tim spent 6 years at L.E.K. Consulting and Arthur D. Little, where he led the Technology & Innovation Practice in the US. Prior to his time in consulting, Tim worked as a scientist at Vertex Pharmaceuticals, Merck Research Labs, and Blend Therapeutics where he led teams in pharmaceutical development focused on oncology, inflammation, and neurology.
Tim received his PhD in Organic Chemistry from MIT under the tutelage of Professor Stephen Buchwald and was a NIH postdoctoral fellow under the late 2008 Noble Laurate Professor Roger Tsien in the field of cancer imaging and targeting. He received a BS in Chemistry from UC San Diego. Tim is a co-author on more than 25 peer-reviewed publications and patents, garnering ~6,000 citations to date.